Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Cara Therapeutics Inc CARA

Healthcare Cannabis
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated... see more

Recent & Breaking News (NDAQ:CARA)

Cara Therapeutics to Sponsor Symposium and Present Poster at the American Academy of Pain Medicine's 31st Annual Meeting

GlobeNewswire March 19, 2015

Cara Therapeutics to Announce Fourth Quarter and Full Year 2014 Financial Results on March 26, 2015

GlobeNewswire March 19, 2015

Cara Therapeutics to Webcast Presentation at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference

GlobeNewswire March 13, 2015

Cara Therapeutics Issued Additional U.S. Patent Covering the Expanded Use of Kappa Opioid Receptor Agonist CR845 and Analogs for the Treatment and Prevention of Pain-Related Conditions

GlobeNewswire February 10, 2015

Earth Science Tech Building A Nutrition Empire Based On High Grade CBD and Nutraceutical Retailing

Accesswire February 4, 2015

Cara Therapeutics to Webcast Presentation at 17th Annual BIO CEO & Investor Conference

GlobeNewswire February 2, 2015

Cara Therapeutics Announces Addition to the NASDAQ Biotechnology Index

GlobeNewswire December 18, 2014

Cara Therapeutics Reports Positive Top-Line Data From Phase 1b Trial of I.V. CR845 in Dialysis Patients

GlobeNewswire December 17, 2014

Enteris BioPharma's Formulation Technology Enables Oral Delivery of Cara Therapeutics' CR845 Peptide for Acute and Chronic Pain in Phase 1a / 1b Trial

PR Newswire December 9, 2014

Novus Becomes an Insurance Leader as MMJ Market Approaches Tipping Point

Accesswire December 8, 2014

Cara Therapeutics Announces Appointment of Joseph Stauffer, D.O., as Chief Medical Officer

GlobeNewswire December 2, 2014

Cara Therapeutics Announces Positive Top-Line Results From Phase 1a / 1b Trial of Tablet Formulation of Oral CR845 for the Treatment of Acute and Chronic Pain

GlobeNewswire December 2, 2014

Cara Therapeutics to Webcast Presentation at 26th Annual Piper Jaffray Healthcare Conference

GlobeNewswire November 25, 2014

Cara Therapeutics to Webcast Presentation at 2014 Stifel Healthcare Conference

GlobeNewswire November 11, 2014

Cara Therapeutics Reports Third Quarter 2014 Financial Results

GlobeNewswire November 10, 2014

Cara Therapeutics to Announce Third Quarter 2014 Financial Results on November 10, 2014

GlobeNewswire November 3, 2014

Cara Therapeutics Announces Positive Results From Human Abuse Liability Trial of Peripheral Opioid for Acute Pain, I.V. CR845

GlobeNewswire October 29, 2014

Cara Therapeutics Announces the Unexpected Death of Chief Medical Officer Dr. Robert Medve

GlobeNewswire October 27, 2014

Cara Therapeutics to Sponsor Symposium at American Academy of Pain Management 2014 Annual Clinical Meeting

GlobeNewswire September 17, 2014

Cara Therapeutics Reports Second Quarter 2014 Financial Results

GlobeNewswire August 7, 2014